Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptorantagonist

Background The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an antiemetic in patients receiving anticancer chemotherapy. Methods in a multicenter, double-blind, placebo-controlled trial involving 159 patients who had not previously received cisplatin, we evaluated the pr evention of acute emesis (occurring within 24 hours) and delayed emesis (oc curring on days 2 to 5) after a single dose of cisplatin therapy (70 mg or more per square meter of body-surface area). Before receiving cisplatin, al l the patients received granisetron (10 mu g per kilogram of body weight in travenously) and dexamethasone (20 mg orally). The patients were randomly a ssigned to one of three treatments in addition to granisetron and dexametha sone: 400 mg of an oral trisubstituted morpholine acetal (also known as L-7 54,030) before cisplatin and 300 mg on days 2 to 5 (group 1), 400 mg of L-7 54,030 before cisplatin and placebo on days 2 to 5 (group 2), or placebo be fore cisplatin and placebo on days 2 to 5 (group 3). Additional medication was available at any time to treat occurrences of vomiting or nausea. Results In the acute-emesis phase, 93 percent of the patients in groups 1 a nd 2 combined and 67 percent of those in group 3 had no vomiting (P<0.001). In the delayed-emesis phase, 82 percent of the patients in group 1, 78 per cent of those in group 2, and 33 percent of those in group 3 had no vomitin g (P<0.001 for the comparison between group 1 or 2 and group 3). The median nausea score in the delayed-emesis phase was significantly lower in group 1 than in group 3 (P=0.003). No serious adverse events were attributed to L -754,030. Conclusions The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin. Moreover, combining L-754,030 with granisetron plus dexamethasone improves the prevention of acute emesis. (N Engl J Med 1999;340: 190-5.) (C) 1999, Massachusetts Medical Society.